Early in 2024, we reported on the FDA's call for new boxed warnings on the labeling of all approved chimeric antigen receptor (CAR) T-cell therapies for the potential risk for secondary T-cell ...

Dr Sattva S. Neelapu discusses data from the ZUMA-5 trial investigating the CAR T-cell therapy Yescarta in relapsed/refractory follicular lymphoma.

Curocell launches Limcato, South Koreas first domestic CAR-T cancer therapy Curocell introduces first local CAR-T therapy, ...

Regulators approved the first bespoke cell therapies for solid tumors this year, while drugmakers expanded and improved upon ...

INR:8703. casino blackjack split Starting next year, a large number of anti-cancer APIs and rare disease APIs will be subject to zero tariffs! The eighth i ...

INR:8784. mastercard bet365 Innovative therapy targeting dual inflammation-related cytokine pathways received FDA breakthrough therapy designation After GMP, GC ...

INR:6441. rummy 366 CD19 CAR-T cell therapy! Gilead's Yescarta treatment of iNHL has a complete remission rate of 80% Another doctor was suspended, his prescription rig ...

INR:1994. kerala lottery bumper list "Pharmaceutical Speed ​​Reading Club" Many Biogen employees were infected with the new coronavirus, and Pien T ...

Gilead stock rated buy for thriving HIV biz, promising oncology pipeline, and long-term growth potential despite volatility.

INR:4214. what happens if a casino overpays you Gilead announces 2019H1 results, CAR-T therapy Yescarta revenue doubles ...

INR:2379. ph bet online casino Gilead's Yescarta was granted orphan drug status by the FDA and included in the priority review in China! R&D Daily丨ShuoShi ...

INR:4681. blackjack tournament las vegas Two blockbuster generic drugs from Qilu were approved: albumin paclitaxel for ...